4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
$9.81
-$0.14(-2.20%)
At close: 4:00 PM EST
$9.81
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$2.47 - $12.34
Previous CloseN/A
Volume165.32K
Average Volume (3M)736.92K
Market Cap
$500.82M
Enterprise Value$461.99M
Total Cash (Recent Filing)$402.65M
Total Debt (Recent Filing)$21.41M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,051,487
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.42
Enterprise Value/Gross Profit-38.63
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$31.43Price Target Upside220.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$7.78M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressionLate‑stage pivotal trial for the wet age‑related macular degeneration program completed enrollment ahead of projections and aligns with regulatory expectations, strengthening prospects for a definitive pivotal readout.
Non‑dilutive Funding For Pipeline ProgramsFull funding from a major foundation for the cystic fibrosis program lowers the need for additional capital and allows continued clinical advancement without immediate shareholder dilution.
Strategic Partnership And FinancingStrategic collaboration with a major pharmaceutical partner provides upfront funding, cost sharing, regulatory and commercial support, and tiered royalties, reducing development risk and improving commercialization prospects.
Bears Say
Clinical Efficacy Uncertainty In Cystic FibrosisInterim cystic fibrosis results reflect modest effects in small patient cohorts and an unclear link between biomarker changes and meaningful clinical outcomes, creating development uncertainty.
Competitive Retina Treatment LandscapeA busy retina market with multiple competing anti‑VEGF therapies and novel entrants could limit market share and put pressure on the commercial outlook for the wet macular degeneration candidate.
Market Adoption And Access BarriersAdoption risk is elevated because established intravitreal treatments and emerging oral options may confine initial use to patients not controlled by standard therapies, reducing near‑term uptake.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $2.46 and its highest was $12.34 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $500.82M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Mar 18, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of -$0.528 by $0.958.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 51,051,487 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of $0.43 in its last earnings report, beating expectations of -$0.528. Following the earnings report the stock price went up 4.907%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.43 (220.39% Upside)
$31.43 (220.39% Upside)
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.09%
12-Months-Change
Fundamentals
Return on Equity
-47.27%
Trailing 12-Months
Asset Growth
-29.81%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$31.43
▲(220.39% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
0.38% Insiders
13.65% Mutual Funds
43.86% Other Institutional Investors
25.02% Public Companies and
Individual Investors